GlassScriptPhysician profile
Janet Bilafer-Steiner
NPI 1457875015
$2,083.35
in general payments reported to CMS, 2019-2025
17 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $379 · 2022: $40.14 · 2023: $507 · 2024: $636 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $777.56 | 2021-2025 | |
| Pfizer INC. | $236.17 | 2021-2024 | |
| Lundbeck LLC | $206.95 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $131.19 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $112.99 | 2021-2025 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $107.26 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $89.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $77.29 | 2024 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $70.24 | 2021-2024 | Gattex, Trintellix |
| Otsuka America Pharmaceutical, INC. | $60.84 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $48.56 | 2025 | Watchman Access System |
| Lilly USA, LLC | $43.00 | 2024-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $40.14 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $23.25 | 2025 | Neffy |
| Allergan, INC. | $21.51 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $20.24 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.83 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Bilafer-Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.